CAS: 356068-94-5 - Toceranib
Formula:C22H25FN4O2
InChI:InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-
InChI key:InChIKey=SRSGVKWWVXWSJT-ATVHPVEESA-N
SMILES:O=C1NC2=CC=C(F)C=C2C1=CC=3NC(=C(C(=O)NCCN4CCCC4)C3C)C
- Synonyms:
- 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-
- 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
- 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide
- Palladia
- Pha 291639
- Su-11654
- Toceranib
Ref: IN-DA00C6I2
1g | 131.00 € | ||
5g | 323.00 € | ||
10mg | 51.00 € | ||
50mg | 55.00 € | ||
250mg | 61.00 € |
Estimated delivery in United States, on Monday 18 Nov 2024
Toceranib
CAS:356068-94-5
Toceranib phosphate, orally active, inhibits RTK, PDGFR, VEGFR, Kit; Kis 5 nM PDGFRβ, 6 nM …
Formula:
C22H25FN4O2
Purity:
97.14%
Color and Shape:
Solid
Molecular weight:
396.46
- Inhibitors
- Tyrosine Kinase/Adaptors
- VEGFR
- PDGFR
- See more categories
- c-Kit
- Toceranib and Impurities
Ref: TM-T13178
10mg | 46.00 € | ||
25mg | 64.00 € | ||
50mg | 87.00 € | ||
100mg | 114.00 € |
Estimated delivery in United States, on Thursday 21 Nov 2024
(Z)-5-(5-FLUORO-2-OXO-2,3-DIHYDRO-1H-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-N-[2-(1-PYRROLIDINYL)ETHYL]-1H-PYRROLE-3-CARBOXAMIDE
CAS:356068-94-5
Purity:
97.0%
Molecular weight:
396.46600341796875
Ref: 10-F387052
10mg | To inquire | ||
50mg | To inquire |
Estimated delivery in United States, on Friday 29 Nov 2024
Toceranib
CAS:356068-94-5
Inhibitor of receptor tyrosine kinases
Formula:
C22H25FN4O2
Purity:
Min. 95%
Molecular weight:
396.46 g/mol
Ref: 3D-FT44529
1g | To inquire | ||
2g | To inquire | ||
5g | To inquire | ||
10g | To inquire | ||
25g | To inquire |
Estimated delivery in United States, on Monday 30 Dec 2024